Latest news
Why Zevra Therapeutics (ZVRA) Is Up 21.6% After Strong MIPLYFFA Uptake And New Real-World Data - simplywall.stsimplywall.st · Sat, 08 Aug 2026 10:47:29 GMTZevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35 - TipRanksTipRanks · Fri, 07 Aug 2026 23:02:28 GMTZevra Therapeutics (ZVRA) Stock Jumps On Profitability While MIPLYFFA Concentration Lingers - simplywall.stsimplywall.st · Fri, 07 Aug 2026 02:18:50 GMTAnalyst Reiterates Buy on Zevra as Strong Miplyffa Performance Offsets Arimoclomol Setback; $24 Price Target Maintained - TipRanksTipRanks · Thu, 06 Aug 2026 17:18:07 GMTBrandon Folkes Reiterates Buy on Zevra Therapeutics, Raising Price Target to $26 on Strong MIPLYFFA-Driven Outperformance - TipRanksTipRanks · Thu, 06 Aug 2026 15:27:30 GMTZevra Pharmaceuticals: Strong Miplyffa Uptake, Arimoclomol EAP Momentum, and EU Re-examination Support Buy Rating - TipRanksTipRanks · Thu, 06 Aug 2026 08:50:06 GMTZVRA: Q2 revenue up 53% to $39.7M, driven by MIPLYFFA growth and robust cash position of $260.2M - TradingViewTradingView · Wed, 05 Aug 2026 22:46:54 GMTZEVRA THERAPEUTICS, INC. 2026: Revenue $39.66M, EPS $0.14— 10-Q Summary - TradingViewTradingView · Wed, 05 Aug 2026 21:21:01 GMT